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Abstract
Background: Cholesterol ester transfer protein (CETP)
plays a pivotal role in the remodelling of triglyceride
(TG)-rich and high-density lipoprotein (HDL) particles.
Sequence variations in the CETP gene may interfere
with coronary atherosclerosis. However, clinical stud-
ies of various CETP polymorphisms have shown con-
troversial data in coronary artery outcome. We aimed
to investigate whether TaqIB CETP gene polymor-
phism could predict clinical outcome in a prospective
cohort of patients hospitalized for an acute coronary
syndrome (ACS).
Methods: Two hundred and seventy consecutive Cau-
casian patients hospitalized for an ACS, and having a
significant coronary artery disease in at least one
major vessel (stenosis )50%), were prospectively
enrolled and followed for 57 months. The mean age
was 65.1"12.5 years, and 77% were males. One hun-
dred and thirty-nine patients (51.5%) suffered from
unstable angina at inclusion and 131 patients (48.5%)
presented with an acute myocardial infarction (MI).
The follow-up data were obtained from question-
naires. The major recurrent events recorded were 32
deaths comprising 28 cardiovascular deaths and 49
combined cardiovascular events (28 cardiovascular
deaths, 19 non-fatal ACS and 2 non-fatal strokes).
CETP genotyping was performed using a restriction
fragment length polymorphism based method.
Results: A significant relation was found between
B2B2 genotype and combined cardiovascular end-
point (p-0.02), mainly driven by a link with cardio-
vascular death (p-0.05). The hazard risk ratio for
cardiovascular death associated with B2B2 genotype
was 2.2 w95% confidence interval (CI): 1.01–4.94,
p-0.05x. In multivariate analyses, no modification
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except for a significant interaction with statin therapy
was observed by inclusion of potential confounders
for the association of B2B2 genotype with cardiovas-
cular death.
Conclusions: These results suggest that patients
homozygous for the B2 allele and not taking statin
had a strong increase of recurrent cardiovascular
event after an initial acute coronary event. This car-
diovascular risk seems to be corrected with statin
therapy.
Clin Chem Lab Med 2009;47:1039–46.
Keywords: acute coronary syndrome; cardiovascular
death; cholesterol ester transfer protein (CETP); gene
polymorphism; prospective study.
Introduction
The inverse relationship between high-density lipo-
protein cholesterol (HDL-C) and the incidence of car-
diovascular disease (1, 2) has stimulated interest for
pharmacological strategies for raising HDL-C levels.
The finding that genetic deficiency of the cholesteryl
ester transfer protein (CETP) in humans was associ-
ated with increased plasma HDL-C concentrations led
to the concept that inhibition of CETP could be an
interesting way for preventing coronary artery dis-
ease. CETP plays a central role in HDL metabolism, in
particular by catalyzing the hetero-exchange of cho-
lesteryl esters (CEs) from HDL particles to apolipopro-
tein B (apoB)-containing particles, and triglycerides
(TGs) from apoB lipoproteins to HDL particles (3).
Numerous studies have shown that plasma concen-
trations of CETP are inversely related to HDL-C con-
centrations. Administration of the CETP inhibitor
torcetrapib was shown to increase HDL-C concentra-
tions by more than 50%. However, the effectiveness
of CETP inhibition as a strategy for anti-atheroscle-
rotic therapy is controversial due to the recent unex-
pected association of torcetrapib with increased
cardiovascular mortality (4–6). Today, the question is
how to better identify patients who might derive
some benefit from such a therapeutic approach. In
this way, analysis of the relationship of genetic homo-
zygous or heterozygous CETP deficiency to cardiovas-
cular risk could be very interesting, but remains
unclear (7–18). The risk of coronary heart disease
might be lower in CETP-deficient heterozygotes, but
CETP deficiency in Japanese-American men was
associated with an increased prevalence of cardiovas-
cular artery disease (CAD) despite modestly increased
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Table 1 Baseline characteristics of the study population
(ns270).
Age, years (mean"SD) 65.1"12.5
Gender (male), n (%) 208 (77)
Diabetes, n (%) 51 (19)
BMI, kg/m2 mean"SD 25.8"3.9
Hypercholesterolemia, n (%) 207 (77)
Hypertriglyceridemia, n (%) 93 (34)
HypoHDLemia, n (%) 115 (43)
Hypertension, n (%) 187 (69)
Current smoker, n (%) 82 (30)
EF-40%, n (%) 21 (8)
MVD, n (%) 186 (69)
Unstable angina, n (%) 139 (51)
MI, n (%) 131 (49)
Previous MI, n (%) 51 (19)
Glycemia, mmol/L 5.95"1.42
Total cholesterol, mmol/L 5.32"1.14
TGs, mmol/L 1.72"1.13
HDL-C, mmol/L 1.19"0.48
LDL-C, mmol/L 3.41"1.00
Fibrinogen, g/L 4.35"1.22
ESR, mm/h 27.38"23.64
Aspirin, n (%) 260 (96)
b-Blocker, n (%) 178 (66)
ACE inhibitor or ARAII, n (%) 140 (52)
Statin, n (%) 188 (70)
Overall mortality, n (%) 32 (12)
Cardiovascular death, n (%) 28 (10)
Combined cardiovascular event, n (%) 49 (18)
Medications are treatment during follow-up. BMI, bodymass
index; EF, ejection fraction; MVD, multiple vessels diseased;
MI, myocardial infarction; TG, triglyceride; HDL-C, high-den-
sity lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; ESR, erythrocyte sedimentation rate; ACE, angio-
tensin converting enzyme; ARAII, angiotensin II receptor
antagonists.
HDL-C (9, 18). A common polymorphism of the CETP
gene located in intron 1 (TaqIB) has consistently been
shown to influence CETP activity and HDL-C concen-
trations. This polymorphism is non-functional by
itself, but is in almost complete linkage disequilibrium
with the –629C/A promoter polymorphism which
directly modulates CETP gene transcriptional activity
(19–22). After an acute coronary syndrome (ACS),
patients with low plasma HDL-C receive clinical ben-
efit from statin therapy. Since genetic variation of the
CETP gene strongly affects HDL-C and possibly statin
therapy, we conducted a prospective study to assess
the potential effect of the TaqIB polymorphism on the
rate of recurrent cardiovascular events in patients
hospitalized for an acute coronary event.
Materials and methods
Study design and patients
Two hundred and eighty-four consecutive patients of Cau-
casian origin, hospitalized from October 1998 to January
2001 at the Cardiology Unit in Bordeaux University Hospital
for an acute coronary event associated with a coronary
artery disease confirmed by coronary angiography on the
basis of a luminal diameter stenosis G50% in at least one
coronary artery, were recruited for this study. Patients of any
age and gender were recruited. Each gave written informed
consent for blood collection for use in a confidential ‘‘deoxy-
ribonucleic (DNA) bank’’, approved by the Local Research
Ethics Committee. Key demographic characteristics at base-
line were recorded using computerized angiographic data
forms, including age, gender, risk factors, clinical presenta-
tion and biological data. Only patients presenting with an
acute coronary event defined as unstable angina or acute
myocardial infarction (MI) were recruited. The diagnosis of
unstable angina included the presence of typical angina at
rest associated with acute or transient ST segment or T wave
changes without enzyme increases. Acute MI was diagnosed
according to the occurrence of chest pain, increased myo-
cardial enzymes (total and creatine kinase-MB and troponin
I Gtwice the upper normal limit) and electrographic changes
(ST elevation or depression). Hypercholesterolemia was
defined as plasma low-density lipoprotein cholesterol (LDL-
C) concentrations )2.58 mmol/L; hypoalphalipoproteinemia
was defined as plasma HDL-C concentrations -1.032
mmol/L for men and 1.29 mmol/L for women; hypertrigly-
ceridemia was defined as plasma TG concentrations
)1.7 mmol/L (23, 24). Hypertension was defined 1) in non-
diabetic patients as systolic pressure )140 mm Hg or dia-
stolic pressure)90 mm Hg; 2) in diabetic patients as systolic
pressure )130 mm Hg or diastolic pressure )80 mm Hg;
3) as a history of hypertension requiring treatment (25). Body
mass index was calculated as body weight in kg divided by
the square of height in meters. Medications at discharge
were noted. As indicated in Table 1, the mean age of the
study population was 65.1"12.5 years, with 77% male. At
inclusion, 139 patients (51.5%) suffered from unstable angina
and 131 patients (48.5%) presented with an acute MI. A pre-
vious MI was found in 51 patients (18.9%). Sixty-nine percent
of the patients presented with multiple coronary stenosis,
and 8% presented with a low ejection fraction (EF) of -40%.
Follow-up
Follow-up data were obtained from questionnaires sent to
the patient or family, and the patient’s general physician and
cardiologist. Questionnaires were sent 2 years following
examination and then every other year. The following
variables were recorded: death, cardiac death, stroke and
ACS. Relevant clinical data were also analyzed for the
patients who were readmitted or died in the hospital. Cardiac
death was defined as that from any cardiac cause (sudden
death, fatal MI, heart failure). Treatment during follow-up,
although not standardized, was recorded. The mean follow-
up period was 57 months. Among the 284 patients included
in this study, 14 patients were lost to follow-up and excluded
from the study. The final analysis was performed using the
270 patients with follow-up information. As indicated in
Table 1, the major events recorded were 32 deaths, consist-
ing of 28 deaths from cardiovascular causes, two from can-
cer, one from lymphoma and one from articular gangrene;
and 49 combined cardiovascular events comprised of 28
deaths from cardiovascular causes, 19 non-fatal ACS and
two non-fatal strokes. Median delay for combined end points
was 12 months.
Lipids and lipoproteins
Total serum cholesterol (TC), TG, and HDL-C concentrations
were determined using enzymatic assay kits (Roche modu-
lar, Roche Diagnostics SA, Meylan, France). LDL-C was cal-
culated using the Friedewald equation (26). Lipid profiles
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Table 2 Distribution of follow-up events according to CETP TaqIB genotypes.
Number of Overall mortality Cardiovascular death Combined CV
subjects (ns32) (ns28) event (ns49)
CETP TaqIB genotypes
B1B1, n (%) 83 7 (8.4) 6 (7.2) 11 (13.3)
B1B2, n (%) 137 16 (11.7) 13 (9.5) 23 (16.8)
B2B2, n (%) 50 9 (17.6) 9 (17.6) 15 (29.4)
Overall p-value 0.253 0.127 0.044
p-Value for B2B2 0.136 0.049 0.017
Differences in genotypes frequencies were evaluated by the x2-test. CV, cardiovascular. Bold: p-0.05.
Figure 2 Death from a cardiovascular cause: survival anal-
ysis (Kaplan-Meier) for 270 coronary patients with ACS
according to CETP TaqIB genotypes.
Figure 1 Combined cardiovascular event: survival analysis
(Kaplan-Meier) for 270 coronary patients with ACS according
to CETP TaqIB genotypes.
obtained the day of ACS diagnosis were the only ones con-
sidered for analysis.
Blood sampling for DNA analysis
All blood samples for DNA analysis were collected at dis-
charge. DNA was extracted from 200 mL of the buffy coat of
a centrifuged EDTA anticoagulated blood sample, with a
QiaAmpDNA minikit (QIAGEN S.A., Courtaboeuf, France)
according to the manufacturer’s protocol.
CETP genotyping
CETP genotyping was performed using a restriction frag-
ment length polymorphism based method. Briefly, polymer-
ase chain reaction (PCR) amplification was performed using
primers surrounding the TaqIB polymorphism in intron 1 of
the CETP gene: 59-CAC ACC ACT GCC TGA TAA CC-39 (for-
ward) and 59-GTG ACC CCC AAC ACC AAA TA-39 (reverse).
The amplification mixture included 25 pmol of each primer,
100 ng genomic DNA, 1x GoTaq reaction buffer, 1.5 mmol/L
MgCl2, 0.2 mmol/L of each dNTP, and 0.5 U of GoTaq DNA
polymerase in a total volume of 25 mL (Promega Corpora-
tion, Madison, WI, USA). Amplification was performed for
35 cycles of 30 s at 958C, 15 s at 608C, and 15 s at 728C with
an initial denaturation period of 5 min at 958C. Approximate-
ly 20 mL of PCR products were digested with the restriction
enzyme TaqI according to the recommendations of the sup-
plier (Fermentas, Life Sciences, St. Re´my les chevreuse,
France). Fragments were separated using 2% MP agarose gel
(Boehringer Mannheim, Mannheim, Germany) and stained
with ethidium bromide. One fragment of 505 bp indicated
the absence of the TaqI restriction site (B2B2 genotype), two
fragments of 415 and 90 bp indicated the presence of the
restriction site (B1B1), and three fragments of 505, 415, and
90 bp indicated heterozygosity for the restriction site (B1B2).
Statistical analysis
Hardy-Weinberg equilibrium was tested using the x2-test
with two degrees of freedom. Differences between the
groups of patients were evaluated with the unpaired t-test
for continuous variables, and with the x2-test for categorical
variables. The cumulative survival plot in relation to CETP
genotypes was estimated by the Kaplan-Meier method with
use of the log-rank test. Hazard risk ratios according to CETP
genotypes were estimated using Cox regression analysis.
The interaction between the CETP TaqIB B2B2 genotype and
statin treatment was tested by introducing a corresponding
interaction term into the Cox model. In survival analyses, the
p-value associated with the genotype was obtained by
assuming a co-dominant allele effect (genotype entered as
an ordinal variable 0, 1, or 2). A p-0.05 was considered
statistically significant. All computations were carried out
with NCSS 2000 (NCSS Inc, Kaysville, UT, USA).
Results
CETP genotypes and clinical outcomes
A significant association was found between the CETP
TaqIB polymorphism and combined cardiovascular
end point (Table 2). Homozygousity for the mutant
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Table 3 Baseline characteristics of patients according to cardiovascular death.
With cardiovascular death Without cardiovascular death p-Value
(ns28) (ns242)
Age, years (mean"SD) 71.0"10.2 64.5"12.6 0.003
Gender (male), n (%) 19 (68) 189 (78) 0.22
Diabetes, n (%) 13 (46) 38 (16) -0.001
BMI, kg/m2 mean"SD 27.2"4.9 25.6"3.8 0.12
Hypercholesterolemia, n (%) 18 (64) 189 (78) 0.10
Hypertriglyceridemia, n (%) 8 (29) 85 (36) 0.46
HypoHDLemia, n (%) 12 (43) 103 (43) ns
Hypertension, n (%) 23 (82) 164 (68) 0.12
Current smoker, n (%) 7 (25) 75 (31) ns
EF-40%, n (%) 6 (21) 15 (6) 0.004
MVD, n (%) 23 (82) 163 (69) 0.15
Unstable angina, n (%) 18 (64) 121 (50) 0.15
MI, n (%) 10 (36) 121 (50) 0.15
Previous MI, n (%) 8 (29) 43 (18) 0.17
Glycemia, mmol/L 6.83"1.83 5.85"1.33 0.01
Total cholesterol, mmol/L 5.54"1.67 5.30"1.06 0.48
TGs, mmol/L 1.98"1.56 1.70"1.08 0.38
HDL-C, mmol/L 1.11"0.33 1.20"0.49 0.24
LDL-C, mmol/L 3.74"1.63 3.37"0.92 0.29
Fibrinogen, g/L 4.88"0.94 4.29"1.23 0.008
ESR, mm/h 41.95"31.66 26.00"22.35 0.044
Aspirin, n (%) 26 (93) 234 (97) 0.31
b-Blocker, n (%) 11 (39) 167 (69) 0.001
ACE inhibitor or ARAII, n (%) 19 (68) 121 (50) 0.07
Statin, n (%) 18 (64) 170 (70) ns
Medications are those prescribed during follow-up. Continuous variables were analyzed with the unpaired t-test and cate-
gorical variables using the x2-test. BMI, body mass index; EF, ejection fraction; MVD, multiple vessels diseased; MI, myocardial
infarction; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ESR, eryth-
rocyte sedimentation rate; ACE, angiotensin converting enzyme; ARA, angiotensin II receptor antagonists. Bold: p-0.05.
Table 4 Hazard risk ratios of future cardiovascular death.
Categories Variables b SE Z-Value p-Value HR CI (95%)
Model 1 B2B2 0.803 0.405 1.98 0.047 2.23 1.01 4.93
Model 2 Age, years 0.049 0.019 2.45 0.014 1.05 1.01 1.09
Gender (male) –0.161 0.425 –0.38 0.706 0.85 0.37 1.96
B2B2 0.778 0.405 1.92 0.055 2.18 0.98 4.82
Model 3 Age, years 0.042 0.021 1.95 0.051 1.04 1.00 1.09
Gender (male) –0.010 0.446 –0.02 0.982 0.99 0.41 2.37
Diabetes 0.949 0.412 2.30 0.021 2.58 1.15 5.79
BMI)25 kg/m2 1.086 0.502 2.16 0.030 2.96 1.11 7.92
Hypertension 0.086 0.520 0.17 0.868 1.09 0.39 3.02
b-Blocker –0.720 0.424 –1.70 0.090 0.49 0.21 1.12
ACE inhibitor or ARAII 0.190 0.447 0.43 0.671 1.21 0.50 2.91
EF-40% 1.348 0.547 2.46 0.014 3.85 1.32 11.24
B2B2 0.892 0.422 2.11 0.035 2.44 1.07 5.58
Multiple variate Cox proportional hazards analyses were performed with cardiovascular death as the dependent variable and
various independent variables as mentioned in the Table. HR, hazard risk ratio; B2B2, patients homozygous for B2 allele;
BMI, body mass index; ACE, angiotensin converting enzyme; ARA, angiotensin II receptor antagonists; EF, ejection fraction.
Bold: p-0.05.
allele was more frequent in the patient group with a
future combined cardiovascular event compared with
non-carriers (p-0.02). This association was primarily
driven by cardiovascular mortality (p-0.05), with no
effect observed for non-fatal ACS or stroke. The rela-
tionship between genotypes and combined cardio-
vascular event or cardiovascular mortality are
illustrated in the Cox survival plots (Figures 1 and 2).
Characteristics of study population according
to cardiovascular death
Major traits significantly associated with cardiovas-
cular death were age, diabetes mellitus, alteration of
left ventricular function, and use of b-blockers (Table
3). It is also interesting to note a more severe inflam-
matory response to the initial coronary event.
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Table 5 Hazard risk ratios of future cardiovascular death and interaction analyses with lipid profile parameters.
Categories Variables b SE Z-Value p-Value HR CI (95%)
Model 1 B2B2 0.803 0.405 1.98 0.047 2.23 1.01 4.93
Model 2 Decreased HDL 0.621 0.516 1.2 0.229 1.86 0.68 5.12
B2B2 1.13 0.605 1.87 0.062 3.10 0.95 10.16
I –0.923 0.983 –0.94 0.348
Model 3 Hypertriglyceridemia –0.335 0.532 –0.63 0.528 0.72 0.25 2.03
B2B2 0.809 0.500 1.62 0.105 2.25 0.84 5.98
I 0.222 0.885 0.25 0.801
Model 4 Hypercholesterolemia 0.511 0.756 0.68 0.499 1.67 0.38 7.34
B2B2 1.96 0.913 2.15 0.031 7.13 1.19 42.70
I –1.71 1.074 –1.59 0.112
Model 5 Statin therapy 0.209 0.521 0.4 0.687 1.23 0.44 3.42
B2B2 1.82 0.633 2.87 0.004 6.15 1.78 21.31
I –1.624 0.820 –1.99 0.047
Multiple variate Cox proportional hazards analyses were performed with cardiovascular death as dependent variable and
various independent variables as mentioned in the Table. HR, hazard risk ratio; HDL, high-density lipoprotein; B2B2, patients
homozygous for B2 allele; I, interaction term which correspond to the co-presence of the first two variables. Bold: p-0.05.
Figure 3 Hazard risk ratios of future cardiovascular death
according to CETP TaqIB genotypes and statin therapy.
Patient characteristics and genotype frequencies
Overall allele frequencies in the study population
were 0.56 for B1 and 0.44 for B2. The distribution of
CETP TaqIB genotypes was B1B1 30.74%; B1B2
50.74%; and B2B2 18.52%. These distributions con-
formed to the Hardy-Weinberg equilibrium. Overall,
demographic and key clinical characteristics of
patients were generally similar by genotype (data not
shown). Importantly, distribution by genotype of
clinical presentation at inclusion was similar (i.e., 44%
of patients homozygous for B2 allele presented with
an acute MI vs. 50% in B1 carriers, ns22 and
111, respectively, ps0.48).
Multivariate analyses
On the basis of a recessive allele effect on risk for
cardiovascular death, the hazard risk ratio associated
with the TaqIB B2 allele was 2.23 w95% confidence
interval (CI): 1.01–4.94; ps0.047x (Table 4). To deter-
mine whether the CETP TaqIB B2B2 genotype
predicted future fatal cardiovascular events independ-
ently of most significant clinical and therapeutic
confounders, several models were fitted (Table 4). No
modification was observed. Similarly, no modification
of the association with B2B2 genotype was observed
when hypoalphalipoproteinemia or hypertriglyceri-
demia status were included in the analysis. Hypercho-
lesterolemia or statin therapy strongly modified this
association (Table 5).
Benefit of statin therapy according to CETP TaqIB
B2B2 genotype
A significant interaction between the CETP TaqIB
B2B2 genotype and statin therapy on cardiovascular
mortality was observed (Table 5; p for interac-
tions0.047). As indicated in Figure 3, patients homo-
zygous for the CETP TaqIB B2 allele and not treated
with statin had a higher prevalence of cardiovascular
events during the follow-up period in comparison
with patients carrying the B1 allele. This apparent
deleterious effect of the B2B2 genotype disappears in
patients treated with statins.
Patient characteristics according to genotype
and treatment status
Patient characteristics differed somewhat by geno-
type and treatment (e.g., age, hyperlipidemia and
concomitant therapy), but major baseline traits asso-
ciated with the B2B2 genotype and absence of statin
medication were hypercholesterolemia and hyperten-
sion (Table 6).
Discussion
The present prospective study reveals a significant
higher frequency of B2 homozygotes than carriers for
the B1 allele in patients experiencing a cardiovascular
death or a combined cardiovascular event. On the
basis of a recessive model, risk value (Hazard Ratio)
for cardiovascular death in B2 homozygous patients
is estimated to be 2.23 with a 95% CI of 1.01–4.94
(ps0.047). This association remained significant even
after the addition of potential confounding variables
in the Cox regression. No modification can be seen
when variables, such as age, gender, diabetes melli-
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Table 6 Baseline characteristics of patients according to statin treatment and CETP TaqIB genotypes.
Statin treatment Untreated Treated Untreated
CETP genotypes B2B2 B2B2 B1a B1a
(ns14) (ns36) (ns152) (ns68)
Age, years (mean"SD) 72.9"10.1b 63.9"13.4 63.5"12.3 68.0"12.0g
Gender (male), n (%) 10 (71) 30 (83) 117 (77) 51 (75)
Diabetes n (%) 4 (29) 5 (14) 31 (20) 11 (16)
BMI, kg/m2 mean"SD 25.2"3.9 25.9"2.9 26.1"4.3 25.1"3.6
Hypercholesterolemia, n (%) 7 (50)c,d 31 (86) 115 (76) 54 (79)
Hypertriglyceridemia, n (%) 3 (21) 14 (39) 59 (39) 17 (25)g
HypoHDLemia, n (%) 4 (29) 12 (33) 69 (45) 30 (44)
Hypertension, n (%) 13 (93)d 27 (75) 104 (68) 43 (63)
Current smoker, n (%) 3 (21) 6 (17)f 55 (36) 18 (26)
EF-40%, n (%) 2 (14) 1 (3) 11 (7) 7 (10)
MVD, n (%) 11 (78) 21 (58) 106 (71) 48 (73)
Aspirin, n (%) 14 (100) 36 (100) 146 (96) 64 (94)
b-Blocker, n (%) 6 (43) 22 (61) 146 (72) 40 (59)g
ACE inhibitor, n (%) 9 (64) 16 (44) 75 (49) 40 (59)
Statin, n (%) 0 (0) 36 (100) 152 (100) 0 (0)
Overall mortality, n (%) 5 (36)b,e 4 (11) 17 (11) 6 (9)
Cardiovascular death, n (%) 5 (36)b,e 4 (11) 14 (9) 5 (7)
Combined cardiovascular event, n (%) 7 (50)b,e 8 (22) 24 (16) 10 (15)
aB1, carriers for B1 allele; bB2B2 homozygous patients without vs. with statin therapy, p-0.05; cB2B2 homozygous patients
without vs. with statin therapy, p-0.01; dB2B2 homozygous vs. carriers for B1 allele in patients without statin therapy, p-0.05;
eB2B2 homozygous vs. carriers for B1 allele in patients without statin therapy, p-0.01; fB2B2 homozygous vs. carriers for B1
allele in patients with statin therapy, p-0.05; gB1 carriers without vs. with statin therapy, p-0.05. Medications are treatment
during follow-up. B2B2, patients homozygous for B2 allele; BMI, body mass index; EF, ejection fraction; MVD, multiple vessels
diseased; ACE, angiotensin converting enzyme.
tus, arterial hypertension or heart failure (defined as
an EF-40%) were added in the model. Similarly, no
modification was observed when variables, such as
low concentrations of HDL-C or hypertriglyceridemia
were added. One variable that significantly modified
this association was the presence or absence of statin
therapy. This suggests that patients homozygous for
the B2 allele and not taking statin had a strong like-
lihood of recurrent cardiovascular events after an ini-
tial acute coronary event, unstable angina or MI. This
risk seems to be corrected with statin treatment.
Since its initial description, the relationship
between the TaqIB genotype and the risk of CAD has
been investigated in numerous population-based
studies. Meta-analysis performed individual patient
data from seven large, population-based studies and
three randomized, placebo-controlled, pravastatin
trials has shown that the TaqI genotype was signifi-
cantly associated with the risk of coronary artery dis-
ease, with a lower risk for B2 carriers. Usually the
significant association between TaqIB genotype and
CAD risk is largely mediated through HDL-C concen-
trations. Our results did not find a lower risk for B2B2
individuals or mediation of the risk through HDL-C
concentrations. These conflicting results could be due
to the fact that our study analyzed recurrent cardio-
vascular events in patients initially recruited for an
initial coronary event. The higher prevalence of
cardiovascular events in B2B2 could suggest a cardio-
vascular death risk independent of HDL-C concentra-
tions. In our study, it did not appear to be dependant
of potential interactions with TG concentrations,
known to affect CETP activity and previously reported
as potentially mediating the CAD risk of CETP (27). It
is difficult to assume that the worst evolution of B2
carriers could be due to more rapid progression of
coronary atherosclerosis which is related to CETP
mass and the B1 allele (14). Moreover, in patients with
coronary artery disease, a previous study demonstrat-
ed that the CETP/–629A allele, in nearly complete con-
cordance with the B2 allele, had a strong protective
effect on future mortality from cardiovascular causes
(7). All of these results suggest that B2 carriers should
be protective against future or recurrent coronary
event.
In order to explain our results, we could not exclude
a selection effect. B2B2 patients, theoretically pro-
tected against coronary artery disease and presenting
with an acute coronary event, could be more sensitive
to undetected or unknown risk factors leading to a
more severe prognosis. In the same way, the appar-
ent deleterious action of the B2 allele could be linked
to an associated genotype, such as hepatic lipase low-
ering gene variants that have been previously report-
ed (27). The impact of the CETP genotype on risk
mediated by a prothrombotic or proarrhythmic effects
of CETP within the vessel wall or within ischemic
myocardium is always possible. Nevertheless, our
finding of a less favorable outcome in B2B2 subjects
is in agreement with results reported by Mohrschladt
et al. (16) in statin-treated patients with familial
hypercholesterolemia.
Based on these results, we hypothesize that in
patients with an ACS, a low CETP level and activity as
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observed in B2B2 subjects could be deleterious. This
can lead to future fatal cardiovascular events by
decreasing the reverse cholesterol transport from
HDL and peripheral tissues to the liver under condi-
tions of efficient hepatic apoB lipoprotein clearance.
The strong amplification of this mechanism by statin
therapy with the significant decrease in LDL-C con-
centrations could explain the disappearance of the
deleterious action of CETP deficiency.
Limitation
The present study has limitations. First, the small
population and small number of events preclude an
exhaustive statistical analysis. Second, the sole inclu-
sion of patients experiencing an ACS could result in
selection bias. Moreover, we did not have the ability
to evaluate lipid parameters before and after statin
therapy. The results on the genotype-statin interac-
tion should thus be considered as a hypothesis.
Because we tested several primary and secondary
hypotheses that were not independent, it was not
possible to correct for multiple testing; hence, the
p-values provided are nominal and require further
confirmation. Finally, serum CETP concentrations and
activity were not measured. Therefore, no association
between them could be observed.
Conclusions
This study demonstrates an association between the
B2B2 genotype in the CETP gene and risk of future
cardiovascular death in patients experiencing an ACS.
Specifically, patients at increased risk are those with
an ACS who are not receiving statin medication and
homozygous for the B2 allele. We speculate that these
patients express an increased sensitivity to less effec-
tive peripheral cholesterol removal. As the action of
CETP may have different effects depending on the
metabolic and/or clinical context, the question is
whether CETP is a good marker and/or therapeutic
target for patients at increased risk of coronary
events.
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